丸美拟赴港上市：项目延期、监管警示与大额分红的三大问号

Core Viewpoint - Marubi Biotech plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and international competitiveness after six years of being listed in A-shares [1][2]. Group 1: Company Actions and Financials - Marubi Biotech announced a delay of two years for its 344 million yuan investment in a "cosmetics intelligent manufacturing factory" project, citing sufficient existing production capacity [1][3]. - The company reported a cash dividend of 0.25 yuan per share, totaling 100 million yuan, on November 14 [1]. - As of the end of Q3 2025, Marubi had 1.592 billion yuan in cash and 413 million yuan in trading financial assets, despite the delay in its investment project [3][4]. Group 2: Performance Metrics - For the first three quarters of 2025, Marubi achieved a revenue of 2.45 billion yuan, a year-on-year increase of 25.51%, while net profit was 244 million yuan, up 2.13% [10][12]. - The company’s cash flow from operating activities increased significantly by 132.19% to 159 million yuan [5]. - Despite revenue growth, the company faced a decline in net profit excluding non-recurring items, which fell by 5.42% to 214 million yuan [10][12]. Group 3: Market Context and Strategic Implications - The trend of A-share companies seeking dual listings in Hong Kong is driven by supportive regulatory policies and a recovering market, with 87 IPOs in Hong Kong in 2025, a 55.36% increase year-on-year [7][8]. - Marubi's actions reflect a broader industry trend where companies are pursuing internationalization strategies amid structural challenges in the market [9][12]. - Analysts question the necessity of Marubi's Hong Kong listing given its substantial idle funds and ongoing delays in existing projects, suggesting a need for clarity on the strategic rationale behind the move [9][12].